FDA Eases Regulations on CBD Products, Boosting Cannabis Stocks
The Food and Drug Administration (FDA) has announced a more relaxed approach to regulating cannabidiol (CBD) products derived from hemp. The decision has sent cannabis stocks soaring, with Tilray and other companies experiencing a significant boost.
In a letter, FDA Commissioner Marty Makary stated that the agency will no longer enforce certain provisions of the Federal Food, Drug, and Cosmetic Act for oral products containing CBD, as long as they are marketed and labeled as dietary supplements and are prescribed by a physician to insurance beneficiaries.
CBD, a non-psychoactive compound found in cannabis, has gained popularity for its potential health benefits. The FDA’s decision to ease regulations on CBD products is expected to increase access to these products for patients seeking alternative treatments.
The move is seen as a positive development for the cannabis industry, which has been growing rapidly in recent years. With the FDA’s more lenient approach, companies like Tilray are likely to benefit from increased demand and a more favorable regulatory environment.
